Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 9;17(3):e0264179.
doi: 10.1371/journal.pone.0264179. eCollection 2022.

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021

Kiersten J Kugeler  1 , John Williamson  1 , Aaron T Curns  1 , Jessica M Healy  1 , Leisha D Nolen  1 , Thomas A Clark  1 , Stacey W Martin  1 , Marc Fischer  1
Affiliations

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021

Kiersten J Kugeler et al. PLoS One. .

Abstract

As of March 2021, three COVID-19 vaccines had been authorized by the U.S. Food and Drug Administration (FDA) for use in the United States. Each has substantial efficacy in preventing COVID-19. However, as efficacy from trials was <100% for all three vaccines, disease in vaccinated people is expected to occur. We created a spreadsheet-based tool to estimate the number of symptomatic COVID-19 cases among vaccinated people (vaccine breakthrough infections) based on published vaccine efficacy (VE) data, percent of the population that has been fully vaccinated, and average number of COVID-19 cases reported per day. We estimate that approximately 199,000 symptomatic vaccine breakthrough infections (95% CI: ~183,000-214,000 cases) occurred in the United States during January-July 2021 among >156 million fully vaccinated people. With high SARS-CoV-2 transmission and increasing numbers of people vaccinated in the United States, vaccine breakthrough infections will continue to accumulate. Understanding expectations regarding number of vaccine breakthrough infections enables accurate public health messaging to help ensure that the occurrence of such cases does not negatively affect vaccine perceptions, confidence, and uptake.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Estimated number of symptomatic COVID-19 cases occurring among the vaccinated population, average daily COVID-19 cases among vaccine eligible age groups, and number of persons fully vaccinated per week in the United States, January–July 2021.
See this image and copyright information in PMC

References

    1. United States Food and Drug Administration. Janssen Biotech Emergency Use Authorization 2021. https://www.fda.gov/media/146303/download.
    1. United States Food and Drug Administration. Pfizer-BioNTech Emergency Use Authorization 2020. https://www.fda.gov/media/144412/download.
    1. United States Food and Drug Administration. ModernaTX Emergency Use Authorization 2020. https://www.fda.gov/media/144636/download.
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15. doi: 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. doi: 10.1056/NEJMoa2035389 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts